Caricamento...
Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation
Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...
Salvato in:
| Pubblicato in: | Clin Appl Thromb Hemost |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7573709/ https://ncbi.nlm.nih.gov/pubmed/33054412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620948585 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|